Carcinoma, Large Cell - 21 Studies Found

Completed : ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
: Non-Small-Cell Lung Carcinoma
: 2006-11-28
:
  • Drug: ZD6474 (vandetanib) once
Completed : An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
:
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasm

: 2003-02-12
: Biological: EP2101
Withdrawn : Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
: Carcinoma, Non-Small-Cell-Lung
: 2012-07-06
: Drug: Temoporfin A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered
Available : An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
:
  • Non-small Cell Lung Cancer
  • Lung Cancer
  • Advanced Malignanci
    : 2016-05-24
    : Drug: Brigatinib Brigatinib will be administered orally to eligible patients with locally advanced or me
Completed : ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
:
  • Non-small Cell Lung Cancer
  • Lung Cancer
  • Advanced Malignanci
    : 2016-03-30
    :
    • Drug: Brigatinib Brigatinib wi
Active, not recruiting : A Phase 2, Multicenter, Randomized Study of AP26113
:
  • Non-small Cell Lung Cancer
  • Lung Cancer
  • Advanced Malignanci
    : 2014-03-18
    :
    • Drug: AP26113 90 mg tablet, ta
Not yet recruiting : Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
:
  • Malignant Neoplasms of Respiratory and Intrathoracic Organs
  • Non-small Cell Lung Cancer

    • : 2017-04-07
    :
    • Radiation: Stereotactic Ablative Radiotherapy

Terminated : Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
: Non-small-cell Lung Cancer
: 2012-01-12
:
  • Radiation: SBRT (stereotactic body radiotherapy)

Terminated : Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
: Non-Small Cell Lung Carcinoma
: 2006-08-15
: Drug: Motexafin gadolinium and pemetrexed 1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during th
Completed : A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
:
  • Non-Small-Cell Lung Carcinoma
  • Carcinoma, Bronchogenic

: 2005-01-29
: Drug: Motexafin Gadolinium Injection
<<< Previous | Next >>>